Cowen restated their buy rating on shares of Allena Pharmaceuticals (NASDAQ:ALNA) in a report published on Friday morning, AnalystRatings.com reports.

Several other equities analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Allena Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 30th. Credit Suisse Group reaffirmed an outperform rating and set a $26.00 price target on shares of Allena Pharmaceuticals in a research note on Monday, August 5th. Wedbush reissued a buy rating and issued a $36.00 price objective on shares of Allena Pharmaceuticals in a report on Tuesday, July 2nd. Roth Capital cut their price objective on Allena Pharmaceuticals from $61.00 to $31.00 in a report on Thursday, August 8th. Finally, ValuEngine raised Allena Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, August 1st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Allena Pharmaceuticals currently has an average rating of Buy and a consensus price target of $23.14.

Shares of ALNA opened at $3.95 on Friday. The company has a market cap of $93.65 million, a PE ratio of -2.30 and a beta of 1.98. Allena Pharmaceuticals has a twelve month low of $3.62 and a twelve month high of $12.00. The business’s 50 day simple moving average is $4.43. The company has a quick ratio of 7.83, a current ratio of 6.80 and a debt-to-equity ratio of 0.22.

Allena Pharmaceuticals (NASDAQ:ALNA) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.01). Equities research analysts forecast that Allena Pharmaceuticals will post -2.04 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wedbush Securities Inc. acquired a new stake in Allena Pharmaceuticals during the 2nd quarter valued at $63,000. Deutsche Bank AG lifted its holdings in Allena Pharmaceuticals by 8.2% during the 4th quarter. Deutsche Bank AG now owns 28,023 shares of the company’s stock valued at $151,000 after purchasing an additional 2,118 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in Allena Pharmaceuticals by 3.8% during the 4th quarter. Squarepoint Ops LLC now owns 43,500 shares of the company’s stock valued at $237,000 after purchasing an additional 1,600 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Allena Pharmaceuticals by 8.1% during the 4th quarter. Geode Capital Management LLC now owns 72,314 shares of the company’s stock valued at $394,000 after purchasing an additional 5,444 shares during the last quarter. Finally, Sphera Funds Management LTD. lifted its holdings in Allena Pharmaceuticals by 24.9% during the 1st quarter. Sphera Funds Management LTD. now owns 431,193 shares of the company’s stock valued at $3,027,000 after purchasing an additional 85,994 shares during the last quarter. 79.70% of the stock is owned by institutional investors.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Read More: Insider Trading – What You Need to Know

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.